Quantum Biopharma (QNTM) Accumulated Depreciation & Amortization (2019 - 2022)

Quantum Biopharma has disclosed Accumulated Depreciation & Amortization across 4 years of filings, most recently posting $4.5 million for Q4 2022.

• Accumulated Depreciation & Amortization for Q4 2022 came in at $4.5 million, up 12.16% year-over-year; the trailing twelve-month figure through Dec 2022 was $4.5 million (up 12.16% YoY), and the FY2022 annual result was $4.5 million, up 12.16% from the prior year.
• Accumulated Depreciation & Amortization came in at $4.5 million for Q4 2022 at Quantum Biopharma, up from $4.0 million in the prior quarter.
• In the past five years, Accumulated Depreciation & Amortization ranged from a high of $4.5 million in Q4 2022 to a low of $1.9 million in Q4 2019.
• The 4-year median for Accumulated Depreciation & Amortization is $4.0 million (2020), against an average of $3.6 million.
• Across the five-year window, Accumulated Depreciation & Amortization jumped 100.74% in 2020 and grew 3.72% in 2021, its largest moves.
• Quantum Biopharma's Accumulated Depreciation & Amortization stood at $1.9 million in 2019, then surged by 100.74% to $3.9 million in 2020, then advanced by 3.72% to $4.0 million in 2021, then advanced by 12.16% to $4.5 million in 2022.
• The last three Accumulated Depreciation & Amortization figures came in at $4.5 million (Q4 2022), $4.0 million (Q4 2021), and $3.9 million (Q4 2020), per Business Quant data.